OnKure Therapeutics

Helicopter landing beside skiers on a snowy summit
OnKure Therapeutics logo
Life Sciences

OnKure Therapeutics is a pharmaceutical company committed to the discovery and development of best-in-class precision medicines targeting biologically validated drivers of cancer that are underserved by available therapies.

CO-INVESTOR

Citadel, Cormorant, Deep Track, Perceptive, Acorn, Samsara.
October 8, 2024

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

OnKure Therapeutics, Inc. (Nasdaq: OKUR) (“OnKure”), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced the completion of its previously announced merger of OnKure, Inc. and Reneo Pharmaceuticals, Inc. (“Reneo”). The combined company will operate under the name OnKure Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Global Market on October 7, 2024 under the ticker symbol “OKUR”.

Read more
May 13, 2024

Reneo Pharmaceuticals and OnKure Announce Proposed Merger

IRVINE, Calif., and BOULDER, Colo.  May 13, 2024 (GLOBE NEWSWIRE) Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) and OnKure, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.   The combined company will focus on advancing OnKure’s pipeline candidates targeting oncogenic mutations in…

Read more